Uptake in non-affected bone tissue does not differ between [18F]-DCFPyL and [68Ga]-HBED-CC PSMA PET/CT

PLoS One. 2018 Dec 20;13(12):e0209613. doi: 10.1371/journal.pone.0209613. eCollection 2018.


Introduction: [68Ga]PSMA-HBED-CC and [18F]DCFPyL show a high potential for the detection of recurrent prostate cancer. While 18F-based tracers have several advantages in availability and image resolution, their sensitivity in the skeleton might be impaired by released [18F]fluoride due to its high bone affinity. In turn, chemically unbound trivalent 68Ga might also accumulate in osseous tissue, in cases of occupied binding sites of plasma proteins and thereby influence bone signal.

Methods: A comparison of average bone SUV was performed in 17 bone-negative and 4 bone-positive patients. All patients underwent PET/CT 125 minutes after application of [18F]DCFPyL and 73 minutes after application of [68Ga]PSMA-HBED-CC at another date.

Results: Native SUVs in unaffected bone tissue and SUVs relative to liver uptake were lower in [18F]DCFPyL (0.49) than in [68Ga]PSMA-HBED-CC scans (0.52). SUVs relative to gluteal muscles did not differ between the two tracers. Average lesional SUVs did not differ between tracers.

Conclusion: No difference of average bone signal intensity was observed for [18F]DCFPyL-PET/CT in comparison to [68Ga]PSMA-HBED-CC scans indicating that diagnostic assessment of the skeleton is not affected by non-specific accumulation of free [18F]fluoride or 68Ga.

MeSH terms

  • Aged
  • Algorithms
  • Antigens, Surface / chemistry
  • Antigens, Surface / isolation & purification*
  • Bone and Bones / diagnostic imaging*
  • Bone and Bones / pathology
  • Gallium Radioisotopes / administration & dosage
  • Gallium Radioisotopes / chemistry
  • Glutamate Carboxypeptidase II / chemistry
  • Glutamate Carboxypeptidase II / isolation & purification*
  • Humans
  • Male
  • Neoplasm Metastasis
  • Neoplasm Recurrence, Local / diagnosis*
  • Neoplasm Recurrence, Local / diagnostic imaging
  • Neoplasm Recurrence, Local / pathology
  • Positron-Emission Tomography
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / diagnostic imaging
  • Prostatic Neoplasms / physiopathology
  • Radiopharmaceuticals / administration & dosage
  • Radiopharmaceuticals / chemistry
  • Skeleton / diagnostic imaging
  • Skeleton / pathology


  • Antigens, Surface
  • Gallium Radioisotopes
  • Radiopharmaceuticals
  • FOLH1 protein, human
  • Glutamate Carboxypeptidase II

Grant support

The authors received no specific funding for this work.